Stay updated with breaking news from Nasdaq Phvs. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Pharvaris (NASDAQ:PHVS – Get Rating) had its price target trimmed by SVB Leerink from $50.00 to $45.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage currently has an outperform rating on the stock. SVB Leerink also issued estimates for Pharvaris’ Q1 2022 earnings at ($0.55) EPS, Q2 2022 earnings at […]
Pharvaris (NASDAQ:PHVS – Get Rating) released its quarterly earnings data on Tuesday. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.70) by $0.61, Fidelity Earnings reports. Shares of PHVS stock traded up $0.60 during mid-day trading on Thursday, reaching $18.66. The stock had a trading […]
Pharvaris (NASDAQ:PHVS – Get Rating) shares gapped down before the market opened on Wednesday . The stock had previously closed at $18.47, but opened at $17.67. Pharvaris shares last traded at $17.41, with a volume of 673 shares changing hands. Separately, Zacks Investment Research upgraded shares of Pharvaris from a “hold” rating to a “buy” […]
ZUG, Switzerland, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization...
Pharvaris Announces Pricing of Upsized Initial Public Offering February 04, 2021 20:08 ET | Source: Pharvaris N.V. Pharvaris N.V. CH Leiden, NETHERLANDS ZUG, Switzerland, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies, including novel, small molecule bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announce...